We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Humacyte, Inc. (HUMA) Dips More Than Broader Market: What You Should Know
Read MoreHide Full Article
Humacyte, Inc. (HUMA - Free Report) ended the recent trading session at $1.03, demonstrating a -3.74% change from the preceding day's closing price. The stock's performance was behind the S&P 500's daily loss of 0.57%. Elsewhere, the Dow saw an upswing of 0.64%, while the tech-heavy Nasdaq depreciated by 1.15%.
Coming into today, shares of the company had gained 19.1% in the past month. In that same time, the Medical sector gained 4.28%, while the S&P 500 gained 2.14%.
Analysts and investors alike will be keeping a close eye on the performance of Humacyte, Inc. in its upcoming earnings disclosure. The company's earnings per share (EPS) are projected to be -$0.08, reflecting a 66.67% increase from the same quarter last year. Meanwhile, our latest consensus estimate is calling for revenue of $1.39 million, up 363.33% from the prior-year quarter.
For the annual period, the Zacks Consensus Estimates anticipate earnings of -$0.3 per share and a revenue of $8.41 million, signifying shifts of -15.38% and +312.41%, respectively, from the last year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Humacyte, Inc. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 6.32% higher. Humacyte, Inc. presently features a Zacks Rank of #2 (Buy).
The Medical - Biomedical and Genetics industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 151, placing it within the bottom 39% of over 250 industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
View the Zacks #1 Rank List
Image: Bigstock
Humacyte, Inc. (HUMA) Dips More Than Broader Market: What You Should Know
Humacyte, Inc. (HUMA - Free Report) ended the recent trading session at $1.03, demonstrating a -3.74% change from the preceding day's closing price. The stock's performance was behind the S&P 500's daily loss of 0.57%. Elsewhere, the Dow saw an upswing of 0.64%, while the tech-heavy Nasdaq depreciated by 1.15%.
Coming into today, shares of the company had gained 19.1% in the past month. In that same time, the Medical sector gained 4.28%, while the S&P 500 gained 2.14%.
Analysts and investors alike will be keeping a close eye on the performance of Humacyte, Inc. in its upcoming earnings disclosure. The company's earnings per share (EPS) are projected to be -$0.08, reflecting a 66.67% increase from the same quarter last year. Meanwhile, our latest consensus estimate is calling for revenue of $1.39 million, up 363.33% from the prior-year quarter.
For the annual period, the Zacks Consensus Estimates anticipate earnings of -$0.3 per share and a revenue of $8.41 million, signifying shifts of -15.38% and +312.41%, respectively, from the last year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Humacyte, Inc. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 6.32% higher. Humacyte, Inc. presently features a Zacks Rank of #2 (Buy).
The Medical - Biomedical and Genetics industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 151, placing it within the bottom 39% of over 250 industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.